We give each case the time and attention it deserves, and we treat everyone who walks through our doors like family.
From auto accidents to defective product injuries to workers’ compensation claims, we’re here to help Louisiana injury victims.
We value building relationships with the many people and organizations that make Louisiana a great place to live.
Dudley DeBosier has a trusted team of personal injury lawyers who have been helping injured people in Louisiana.
Low testosterone, sometimes referred to as “Low T”, is a medical condition that can affect men’s sex drive, mood, energy levels, muscle mass, and bone strength. A variety of patches, injections, gels—including the prescription drug AndroGel®— and pills are marketed to men as ways to increase testosterone levels. But testosterone therapy has been linked to an increased risk of cardiovascular injuries in some male patients. These injuries can include:
If you or someone you love suffered a clotting injury or developed a cardiovascular illness after using a testosterone replacement therapy product, you may be entitled to compensation for your damages. Contact our drug injury lawyers today, and let us protect your legal rights.
Low T drugs come in several different forms and are marketed under many different brand names, including:
A study published in The Journal of the American Medical Association reports a 30 percent increase in the risk of heart attack, stroke, pulmonary embolism, DVT, and even death in men who take these drugs. Another study of more than 55,000 male patients reveals that men over age 65 are twice as likely to have a heart attack after taking ”Low T” drugs for as little as three months. The risk of heart attack also doubles for men under age 65 if they have a history of heart disease.
The same study also concludes that, compared to “Low T” drugs, erectile dysfunction drugs—also marketed as methods to increase male sexual performance—are much less likely to increase the risk of heart attack in men under age 65 who have a history of heart disease.
These risks have led to a U.S. Food and Drug Administration (FDA) investigation into the link between “Low T” treatments and cardiovascular problems.
Never stop taking any prescribed medication without first asking your doctor. But if you or your husband, son, father, or other loved one suffered a heart attack, stroke, or other clotting injury after taking testosterone-boosting products, the drug’s manufacturer may be to blame. Our drug injury lawyers can help you get the money you need for your medical bills, lost wages, and pain and suffering. Don’t wait. Give us a call today and get a free, confidential consultation.
AndroGel®is a registered trademark of AbbVie Inc. Androderm® is a registered trademark of Watson Laboratories. Axiron® is a registered trademark of Eli Lilly and Company. Delatestryl® and Fortesta® are registered trademarks of Endo Pharmaceuticals. Testim® and Striant® are registered trademarks of Auxilium Pharmaceuticals. Trademarked names are used only for identification purposes.
This law firm is not affiliated with, sponsored by, or associated with AbbVie Inc., Watson Laboratories, Eli Lilly and Company, Endo Pharmaceuticals, Auxilium Pharmaceuticals, Forbes, The Journal of the American Medical Association, or the U.S. Food and Drug Administration.
Do not stop taking a prescription medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death.
Cases may be referred to another attorney or law firm.
During this time of uncertainty, please know that we are here and ready to help.
If you’ve been injured, we can arrange a virtual meeting in order to start work on your case right away.
While COVID-19 presents a danger to our community, we will adhere to Louisiana State Law and Gov. John Bel Edwards's recommendations, and close our physical office. However, we remain fully operational, and we’ll continue to offer our services via telecommunications.
Please click here to learn more about our business continuity plan.